Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNA1: AKP-022 in uterine fibroid–associated heavy menstrual bleeding
jRCT2071240087Phase 3Active, not recruiting
- Sponsor
- ASKA Pharmaceutical Holdings Co., Ltd.
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of relugolix + estradiol + norethindrone in Fibromyoma (LM) and hypermenorrhea (3 arms), sponsored by ASKA Pharmaceutical Holdings Co., Ltd. Primary endpoint: Proportion of participants with low PBAC score. Started Feb 2025; status: active, not recruiting.
02
Drugs
relugolix + estradiol + norethindrone
03
Conditions
Fibromyoma (LM)hypermenorrhea
Beyond the preview
Go deeper on jRCT2071240087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240087.